To further analyze KCZ+BZA combinatorial treatment, cell-based viability assays were conducted to determine if KCZ+BZA combination therapy synergizes against HER2-enriched breast cancer and TNBC cells under adherent conditions. This evidence concerns the gene ERBB2 and breast cancer.